Ibandronic acid 150mg oral

Green-G

Brand Name(s):Bonviva

Indication:Osteoporosis

Rationale:

Considered:Nov-05

Review Date:Aug-22

Comments:
NICE TA464
Bisphosphonates for treating osteoporosis
Aug 2017
…………………………
Drug Safety update
Bisphosphonates: very rare reports of osteonecrosis of the external auditory canal
Details at: https://www.gov.uk/drug-safety-update/bisphosphonates-very-rare-reports-of-osteonecrosis-of-the-external-auditory-canal
Dec 2015
…………………………
Drug Safety update
Bisphosphonates: osteonecrosis of the jaw
Details at:https://www.gov.uk/drug-safety-update/bisphosphonates-osteonecrosis-of-the-jaw
November 2009
…………………………
Information and advice for healthcare professionals and patients to minimise risk of oesophageal adverse reactions with oral bisphosphonates:

* Alendronate and oral ibandronate should not be given to patients with abnormalities of the oesophagus and/or other factors which delay oesophageal emptying such as stricture or achalasia. Risedronate should be used with caution in such patients
* Alendronate, oral ibandronate, and risedronate should be used with caution in patinets with active or recent upper gastrointestinal problems
*In patients with known Barrett’s oesophagus, prescribers should consider the benefits and potential risks of alendronate and oral ibandronate on an individual basis.

Advice for patients:

* Patients should be advised about the importance of adhering to dose instructions. Tablets should be swallowed whole with at least 200 mL water on an empty stomach immediately after getting up in the morning. Patients should stay fully upright for at least 30 minutes or 1 hour after taking the tablet and before taking any food, drink, or other medicine as outlined in the product information

MHRA Drug Safety Update Volume 4, Issue 4 November 2010

Ibandronate may be an alternative in patients who find the current weekly or daily regimens inconvenient. It offers no advantage over once weekly alendronate.